Integrated Shield riders: Fresh focus on cancer drug cover, brace for premium hikes
IP riders now have additional cancer drug benefits far more than the base plans, raising the question of whether current premiums are sustainable
DeeperDive is a beta AI feature. Refer to full articles for the facts.
RIDERS to supplement private Integrated Shield Plans (IPs) are set to take on new significance for policyholders, particularly if you are concerned about the extent of cancer drug coverage.
The big question is – are today’s rider premiums sustainable given the riders’ enlarged role in outpatient cancer cover?
Insurers in the IP scheme recently rolled out their base IP plans and riders, with reference to the caps for cancer drug coverage, in line with the cancer drug list (CDL) issued by the health ministry last year.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
S-E Asia tourism takes hit from Middle East crisis, but intra-regional travel could spell hope
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result